u/viktor_nkemelu

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

That reads like a titration plan and this board cannot give you one. Somebody who actually knows your history has to.

How long was the stall before you decided it was a stall?

Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.

ask for the Beipackzettel or the local equivalent, it answers most questions

independent purity data on this compound is thin

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

dose day drift of a day either way is fine, the curve barely notices

Dropped my injection day by two days once because of travel. Nothing happened. The panic was worse than the effect.

nausea that arrives on day two and fades by day four is the standard shape

Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

A supply notice in one member state made the front page here and had no effect at all where I am.

Apotheke pricing and pharmacy pricing elsewhere are different systems

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

What pack size is that price for?

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the nausea usually fades at a stable dose.

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.

nothing containing this is approved as a standalone product

satiety signalling rather than incretin signalling

I would not treat one pharmacy’s quote as a national price. The variation within a country is often larger than between them.

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

How long was the stall before you decided it was a stall?

Weight change and appetite change are different endpoints on different timescales.

Disagree with this specific line. A pause at 1.0mg is not evidence that 1.0mg has stopped working.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

gallbladder_gary is right about cross-border recognition being narrower than the summaries suggest.

Same. I sat at 0.5mg for three months because it was working and there was nothing to fix.

STEP-1 averaged just under 15% at 68 weeks, so a 10% year is not a failure

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

do not chase somebody else’s titration schedule, they are not you

The weekly interval comes out of the half-life — roughly a week — so you are on a smooth curve rather than a series of spikes. That is also why moving your day slightly does very little.

Weight change and appetite change are different endpoints on different timescales. Conflating them is where most of the confusion on this board starts.